News | April 09, 2007

New Omega 3 Surgical Mesh from Atrium Medical FDA Cleared

April 10, 2007 - Atrium Medical Corp. has obtained FDA clearance for a new Omega 3 surgical mesh product called C-QURLite Mesh.

This new product is indicated for use in the surgical repair and reinforcement of soft tissue, including hernia repair - a common procedure performed more than 700,000 times in the U.S. each year. This novel technology combines Atrium's ProLite Ultra polypropylene surgical mesh with a proprietary, pharmaceutical grade Omega 3 fatty acid bio-absorbable gel coating. Unlike traditional tissue separating mesh products, C-QURLite Mesh enhances the handling stiffness and healing response in pre-peritoneal placement when compared to other "bare" polymer mesh products currently used for hernia repair.

C-QURLite Mesh is constructed from the refined ProLite Ultra polypropylene monofilament, providing a low profile, strong, lightweight base structure. The novel all natural Omega 3 gel coating is then applied in a proprietary method, coating each monofilament of the mesh to enhance material handling and subsequent healing. This non-polymeric, bio-absorbable coating has demonstrated in pre-clinical studies to significantly improve anatomical conformance by reducing aggressive, dense acellular collagen formation known to induce adhesions following surgery.

Atrium's discovery of combining inert thin wall polypropylene mesh with an Omega 3 biological coating in pre-clinical studies has demonstrated minimization of peritoneal tissue attachment as well as a significant reduction in both foreign body reaction and inflammation, resulting in a well healed, reinforced soft tissue repair. The novel C-QURLite Mesh BAO coating (BioAbsorbable Oil) also enhances ease of handling and tissue plane placement, which subsequently forms into an elegant soft and flexible implant. It offers improved stiffness and handling qualities preferred by many of today's discriminating surgeons while maintaining excellent see-thru visibility to underlying tissue landmarks for improved anatomical orientation during surgical installation.

The use of Atrium's all natural Omega 3 bio-absorbable coating with its advanced lightweight surgical mesh provides today's clinicians with a broad spectrum of options for both laparoscopic and open surgical repair. This first to market BAO coating technology enables cells to freely grow through the porous mesh implant during healing immediately following soft tissue repair. Atrium's C-QURLite Mesh will be available in a wide variety of preferred anatomical laser cut shapes and sizes mid-year 2007.

Related Content

First Cancer Patient Treated With Accuray Radixact System With Synchrony Motion Tracking
News | Image Guided Radiation Therapy (IGRT) | August 21, 2019
Physicians at the Froedtert & the Medical College of Wisconsin (MCW) Clinical Cancer Center in Milwaukee have...
MD Anderson to Expand Proton Therapy Center

The MD Anderson Proton Therapy Center expansion is expected to be completed in 2023. Rendering courtesy of Stantec.

News | Proton Therapy | August 08, 2019
The University of Texas MD Anderson Cancer Center unveiled plans to expand its Proton Therapy Center during a...
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
The Beamscan 3-D water phantom with the Varian Halcyon radiotherapy system

The Beamscan 3-D water phantom with the Varian Halcyon radiotherapy system. Image courtesy of PTW.

News | Quality Assurance (QA) | July 08, 2019
At this year’s American Association of Physicists in Medicine (AAPM) show, July 14-18 in San Antonio, Texas, PTW will...
Study Identifies MRI-Guided Radiation Therapy as Growing Market Segment
News | Image Guided Radiation Therapy (IGRT) | June 06, 2019
Revenues from the magnetic resonance imaging (MRI)-guided radiation therapy systems market exceeded $220 million in...
Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Accuray Launches Synchrony Motion Tracking and Correction Technology for Radixact System
Technology | Image Guided Radiation Therapy (IGRT) | April 24, 2019
Accuray announced the launch of its Synchrony motion tracking and correction technology to be used with the Radixact...
FDA Clears Advancements for Viewray MRIdian Radiation Therapy System
Technology | Image Guided Radiation Therapy (IGRT) | February 21, 2019
February 21, 2019 — ViewRay Inc. received 510(k) clearance from the U.S.
Elekta Unity MR-Linac Earns FDA Clearance
Technology | Image Guided Radiation Therapy (IGRT) | February 07, 2019
The Elekta Unity magnetic resonance radiation therapy (MR/RT) system recently received 510(k) premarket notification...